ZnT8 (zinc transporter 8) antibodies are markers of an autoimmune attack on pancreatic beta cells. Testing helps diagnose type 1 diabetes and latent autoimmune diabetes in adults by detecting an immune response against the beta-cell zinc transporter. A positive result supports autoimmune diabetes, helps distinguish it from type 2, and can help predict disease onset or progression when found with other autoantibodies.

Reference ranges for ZnT8 autoantibodies vary by laboratory. Generally a normal (negative) result is reported as less than about 15 U/mL; values above the lab-specific cutoff (often ~15–30 U/mL) are considered positive or indeterminate and may indicate autoimmune (type 1) diabetes. Always interpret results using the lab’s reference range and clinical context; discuss abnormal results with your clinician.

The ZnT8 (zinc‑transporter 8) autoantibody blood test typically costs about $50–$250 in the US, £40–£150 privately in the UK, and roughly ₹700–₹3,000 in India. Prices vary by laboratory, whether it’s ordered as part of an autoantibody panel, and insurance or national‑health coverage. Ask your clinician or local diagnostic lab for exact pricing and reimbursement details.

A positive antibody test usually means you were previously infected or vaccinated and your immune system made antibodies. It does not reliably prove current infection or the degree or duration of protection, and antibody levels vary. False positives can occur. For active infection testing, symptoms or PCR/antigen tests are needed. Discuss results and next steps with a healthcare professional.

Zinc transporter 8 (ZnT8, SLC30A8) is primarily linked to diabetes. Autoantibodies to ZnT8 are important markers of type 1 autoimmune diabetes (including latent autoimmune diabetes in adults), while genetic variants in SLC30A8 affect insulin secretion and alter type 2 diabetes risk. Some variants are protective, and ZnT8 involvement has also been investigated in gestational diabetes and beta‑cell dysfunction.

Autoantibodies (GAD, IA‑2, insulin autoantibodies) strongly indicate autoimmune type 1 diabetes when present—especially if multiple antibodies are detected. However, antibodies alone don’t definitively confirm diagnosis; clinicians also use symptoms, blood glucose/HbA1c and C‑peptide levels to assess insulin production. Some people with type 1 can be antibody‑negative, so results are interpreted in clinical context.